Keros Therapeutics (KROS) Retained Earnings (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Retained Earnings came in at $1.2 billion in Q4 2025, up 305.61% YoY from $288.3 million in Q4 2024, and up 355.17% on a QoQ basis from -$458.3 million in Q3 2025.
Keros Therapeutics (KROS) Retained Earnings (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Retained Earnings data on file, last reported at $1.2 billion in Q4 2025.
- Quarterly Retained Earnings rose 305.61% year-over-year to $1.2 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 billion (up 305.61% YoY) and the FY2025 annual result came in at $1.2 billion, up 305.61% from the prior year.
- Retained Earnings grew to $1.2 billion in Q4 2025, from -$458.3 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1.2 billion in Q4 2025 to a low of -$568.8 million in Q4 2024.
- A 5-year average of $289.9 million and a median of $369.2 million in 2021 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2021 — Retained Earnings jumped 1143.9% — and 2023, when it slumped 177.59%.
- Tracing KROS's Retained Earnings over 5 years: stood at $366.9 million in 2021, then soared by 37.86% to $505.9 million in 2022, then slumped by 175.4% to -$381.4 million in 2023, then slumped by 49.12% to -$568.8 million in 2024, then surged by 305.61% to $1.2 billion in 2025.
- The last three Retained Earnings figures came in at $1.2 billion (Q4 2025), -$458.3 million (Q3 2025), and $1.2 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | 1.18 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.18 Bn |
| Dec 31, 2025 | 1.17 Bn |
| Sep 30, 2025 | -458.30 Mn |
| Jun 30, 2025 | 1.16 Bn |
| Mar 31, 2025 | 1.15 Bn |
| Dec 31, 2024 | -568.78 Mn |
| Sep 30, 2024 | 1.06 Bn |
| Jun 30, 2024 | 890.71 Mn |
| Mar 31, 2024 | -424.54 Mn |
| Dec 31, 2023 | -381.43 Mn |
| Sep 30, 2023 | -341.18 Mn |
| Jun 30, 2023 | 628.00 Mn |
| Mar 31, 2023 | -264.24 Mn |
| Dec 31, 2022 | 505.86 Mn |
| Sep 30, 2022 | 439.74 Mn |
| Jun 30, 2022 | 386.41 Mn |
| Mar 31, 2022 | 371.43 Mn |
| Dec 31, 2021 | 366.93 Mn |
| Sep 30, 2021 | -116.82 Mn |
| Jun 30, 2021 | -96.52 Mn |